Golden Oyster Mushroom

Metadata

Regulatory Status

China

• Status: Cultivated as an edible mushroom with growing commercial production. Native to northern China and increasingly cultivated on agricultural waste substrates.
• Chinese Pharmacopoeia: Not listed as an official drug.
• Traditional use: Consumed as a food in Chinese folk medicine traditions, associated with general health promotion and tonification.

Japan

• Status: Known as tamogitake. Native to Japan and consumed as a culinary mushroom.
• Japanese Pharmacopoeia: Not listed.
• Traditional use: Traditional edible mushroom, particularly in northern Japan. Not formally classified in kampo medicinal traditions.

United States

• FDA GRAS status: No specific GRAS determination.
• Dietary supplement: Not widely marketed as a dietary supplement. Available through specialty mushroom cultivators primarily as a culinary product.

European Union

• Novel food status: No specific novel food authorization for P. citrinopileatus extracts. The mushroom is available in some EU markets as a specialty food product.
• EMA/HMPC: No monograph or assessment report.

Korea

• Status: Commercially cultivated and sold as an edible mushroom. Subject of active research by Korean agricultural and food science institutions.

Conditions & Indications

Primary: Immune Modulation (Preclinical Evidence Only)

• Polysaccharide-mediated immune activation: Polysaccharide PCP-1 from P. citrinopileatus activates the p62/Keap1/Nrf2 signaling pathway, modulates the Th1/Th2 balance, and enhances cellular immunity by boosting splenic lymphocyte proliferation and natural killer (NK) cell cytotoxicity. These effects have been demonstrated in cell culture and animal models.
• Macrophage stimulation: Polysaccharides enhance macrophage phagocytic activity and promote pro-inflammatory cytokine production (TNF-alpha, IL-6) through NF-kB pathway activation, consistent with the innate immune stimulation profile of other Pleurotus beta-glucans.

Secondary: Metabolic Support and Hypoglycemic Activity (Preclinical Evidence Only)

• Anti-obesity and metabolic syndrome: An ethanolic extract (PCE) significantly inhibited high-fat diet-induced weight gain, fat accumulation, and glucose intolerance in diet-induced obese mice. The extract demonstrated beneficial effects on liver and kidney function markers in the same model.
• Alpha-glucosidase inhibition: Polysaccharides from P. citrinopileatus fermentation broth inhibit alpha-glucosidase (IC50 = 0.556 mg/mL) through non-competitive inhibition, suggesting potential for modulating postprandial blood glucose. A mycelial polysaccharide (PNLP-3) also inhibits alpha-amylase (IC50 = 9.53 mg/mL).
• Blood glucose reduction: In streptozotocin-induced diabetic mice, high-dose (6 g/kg) P. citrinopileatus buccal tablets produced a 29.1% reduction in blood glucose levels after 3 weeks of administration, with concurrent improvements in lipid profiles.

Secondary: Antioxidant Activity (Preclinical Evidence Only)

• Ergothioneine content: P. citrinopileatus contains the highest ergothioneine levels among commonly cultivated Pleurotus species (0.22—3.94 mg/g dry weight), making it a particularly valuable dietary source of this naturally occurring antioxidant amino acid.
• Polysaccharide antioxidant effects: PCP-2, a galactoglucan with molecular weight of 1.52 x 10^6 Da, significantly reduced reactive oxygen species and enhanced antioxidant enzyme activities in UVB-exposed zebrafish models.
• Phenolic compound activity: Ethanolic extracts exhibit higher antioxidant activity than water extracts, attributed to phenolic compounds including gallic acid and catechin.

Emerging/Preclinical

• Antitumor activity: Polysaccharides have shown antitumor activity in H22 tumor-bearing mice models. Bioactive compounds including ergosterol, glucans, and proteoglycans have been correlated with antitumor effects in the broader Pleurotus genus.
• Antimicrobial effects: Ethanolic and aqueous extracts demonstrate antimicrobial activity against selected bacterial and fungal pathogens in vitro.
• DNA protection: Extracts have shown DNA-protective effects against oxidative damage in cell culture models.
• Hypolipidemic activity: Lovastatin (mevinolin) content may contribute to cholesterol-lowering potential, though the naturally occurring levels are substantially lower than pharmaceutical statin doses.

Mechanism of Action

Primary Mechanisms

1. Beta-glucan immune activation via Nrf2 pathway: Polysaccharides from P. citrinopileatus (PCPs) activate innate immunity through a distinctive mechanism involving the p62/Keap1/Nrf2 signaling pathway, in addition to the canonical dectin-1/TLR pathway shared with other mushroom beta-glucans. Nrf2 activation upregulates antioxidant response element (ARE)-driven gene expression while simultaneously modulating the Th1/Th2 cytokine balance toward enhanced cellular immunity. This dual antioxidant-immunomodulatory mechanism provides a rationale for combined anti-inflammatory and immune-supporting effects.

2. Alpha-glucosidase and alpha-amylase inhibition: Acid polysaccharides from fermentation broth inhibit alpha-glucosidase through non-competitive binding, reducing the rate of disaccharide hydrolysis and slowing postprandial glucose absorption. The mechanism is analogous to acarbose-type pharmaceutical alpha-glucosidase inhibitors, though with lower potency. Alpha-amylase inhibition provides an additional target for carbohydrate digestion modulation.

3. Ergothioneine cytoprotection: Ergothioneine, present at exceptionally high concentrations in P. citrinopileatus compared to other cultivated mushrooms, acts as a potent antioxidant through direct scavenging of hydroxyl radicals, hypochlorous acid, and peroxynitrite. It accumulates in tissues with high oxidative stress through the specific transporter OCTN1 (SLC22A4), providing targeted cytoprotection to mitochondria and other organelles. Ergothioneine has been proposed as a “longevity vitamin” due to its unique biological distribution and protective roles.

Secondary Mechanisms

• Lovastatin-mediated cholesterol modulation: Naturally occurring lovastatin (mevinolin) in P. citrinopileatus inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis. However, the concentrations in whole mushroom are substantially lower than pharmaceutical statin doses, and the contribution of dietary lovastatin from mushroom consumption to lipid-lowering effects is uncertain.
• Adipogenesis inhibition: The ethanolic extract’s anti-obesity effects in diet-induced obese mice involve inhibition of adipocyte differentiation and lipid accumulation, likely through modulation of PPARgamma and C/EBPalpha transcription factor activity.
• NK cell cytotoxicity enhancement: Polysaccharide-driven increases in NK cell activity may contribute to immune surveillance against viral infections and tumor cells, though this has only been demonstrated in animal splenocyte models.

Clinical Evidence Summary

No human clinical trials have been published for Pleurotus citrinopileatus or its extracts as of this writing. All evidence for bioactive properties derives from in vitro cell culture studies and in vivo animal models.

Key Preclinical Studies

Evidence Limitations

• No human clinical trials: The most significant limitation. All biological activity data derives from cell culture and animal models.
• Combination product confounding: The most relevant in vivo study for hypoglycemic effects used a combination product (P. citrinopileatus + H. erinaceus), making it impossible to attribute effects specifically to the golden oyster mushroom.
• Extract heterogeneity: Studies use different extraction methods (hot water, cold water, ethanolic, alkaline), yielding products with different bioactive profiles and making cross-study comparison difficult.
• Dose translation uncertainty: Effective doses in animal models (e.g., 6 g/kg in mice) have not been validated for human oral bioavailability or efficacy.
• Limited independent replication: Most studies originate from Chinese and Asian research groups, with limited international replication.
• Ergothioneine attribution: While P. citrinopileatus is an excellent ergothioneine source, the specific contribution of ergothioneine to the observed biological effects of whole extracts has not been isolated from the effects of other bioactive compounds.

Safety Profile

General Assessment

Golden oyster mushroom has a long history of safe consumption as a culinary mushroom in Japan, China, and Korea. It is increasingly cultivated worldwide as a gourmet food. No adverse effects from normal culinary consumption have been documented. Safety data for concentrated extracts at supplemental doses is limited to preclinical studies that have not reported significant toxicity.

Contraindications

• Mushroom allergy: Individuals with known allergies to Pleurotus species or other mushrooms should exercise caution. Occupational exposure to oyster mushroom spores has been associated with allergic respiratory reactions in mushroom farm workers, though this pertains to spore inhalation rather than oral consumption.
• Pregnancy and lactation: No safety data exists for concentrated extracts during pregnancy or lactation. Culinary consumption at normal dietary levels is presumed safe.

Drug Interactions

No drug interactions have been documented. Theoretical interactions based on preclinical activity:

• Antidiabetic medications: Theoretical additive hypoglycemic effect based on alpha-glucosidase inhibition and glucose uptake enhancement demonstrated in preclinical models. Monitor blood glucose if consuming regularly alongside insulin or oral hypoglycemics.
• Statin medications: Naturally occurring lovastatin content could theoretically interact with pharmaceutical statins, though dietary levels are very low relative to therapeutic statin doses. Clinical significance is minimal.
• Immunosuppressants: Theoretical concern that beta-glucan immunostimulatory activity could counteract immunosuppressive therapy.

Side Effects

• No side effects have been reported from culinary consumption.
• Allergic reactions are possible in sensitized individuals, as with all mushroom species.
• Spore inhalation during cultivation can cause occupational respiratory hypersensitivity in some workers (relevant to growers, not consumers).

Toxicology

• No specific toxicity has been documented for P. citrinopileatus at culinary or research doses.
• The species is widely recognized as safe for human consumption as a food.
• Heavy metal bioaccumulation is a general concern for all cultivated mushrooms; substrate quality and growing conditions affect heavy metal content.

Clinical Dosage

Culinary Use (Food)

• Fresh fruiting body: No established medicinal dose. Consumed as a culinary ingredient, typically 50—150 g fresh weight per serving.
• Dried fruiting body: Approximately 5—15 g dried weight per serving.

Polysaccharide Extracts (Preclinical Only)

• No established human clinical dose. Preclinical animal studies have used:
  • Ethanolic extract: effective at doses reducing weight gain in diet-induced obese mice
  • Buccal tablets: 6 g/kg body weight in diabetic mice (combination product with H. erinaceus)
  • In vitro polysaccharide concentrations: 25—500 micrograms/mL
• These doses cannot be directly translated to human recommendations without pharmacokinetic and clinical dose-finding studies.

Ergothioneine Considerations

• P. citrinopileatus is one of the richest natural dietary sources of ergothioneine (0.22—3.94 mg/g dry weight).
• Dietary ergothioneine intake of approximately 5 mg/day has been associated with health benefits in observational studies of mushroom consumption.
• Regular dietary consumption of golden oyster mushroom could meaningfully contribute to ergothioneine intake, though optimal therapeutic doses for specific conditions have not been established.

Form Selection Guidance

Given the absence of clinical evidence, golden oyster mushroom is best regarded as a nutritious culinary mushroom with promising preclinical research. Hot-water preparation extracts beta-glucan polysaccharides, while ethanolic extraction captures ergothioneine and phenolic compounds more efficiently. Dual extraction would provide the broadest bioactive spectrum, though this approach has not been validated clinically.

Sources

• Hu S, Li H, Zhang H, Wang J, Zhao Y. Structural Characterization and Immunomodulatory Effects of Polysaccharide PCP-1 from Pleurotus citrinopileatus. Food Funct. 2024;15:3456-3468
• Chen JT, Su HJ, Huang LH. Ethanolic Extract of the Golden Oyster Mushroom, Pleurotus citrinopileatus (Agaricomycetes), Alleviates Metabolic Syndrome in Diet-Induced Obese Mice. Int J Med Mushrooms. 2018;20(1):33-44
• Chen W, Li M, Dong Q, Zhang J, Huang X. Hypoglycemic Effect of Pleurotus citrinopileatus and Hericium erinaceus Buccal Tablets on Diabetic Mice. Biology. 2025;14(11):1591
• Xu J, Wu F, Li L, Li Y, Zhang Y. A novel acid polysaccharide from fermented broth of Pleurotus citrinopileatus: Hypoglycemic activity in vitro and chemical structure. J Mol Struct. 2020;1221:128825
• Li Q, Wang W, Zhu Y, Chen Y, Zhang W. A novel polysaccharide from Pleurotus citrinopileatus mycelia: Structural characterization, hypoglycemic activity and mechanism. Food Funct. 2020;11(8):7083-7096
• Hu SH, Liang ZC, Chia YC, Lien JL, Chen KS, Lee MY, Wang JC. Molecular weight affected antioxidant, hypoglycemic and hypotensive activities of cold water extract from Pleurotus citrinopileatus. J Ethnopharmacol. 2017;202:47-56
• Lee YL, Huang GW, Liang ZC, Mau JL. Antioxidant properties of three extracts from Pleurotus citrinopileatus. LWT Food Sci Technol. 2007;40(5):823-833
• Kocak E, Sengul M. Medicinal Properties of the Golden Oyster Mushroom, Pleurotus citrinopileatus (Agaricomycetes), Grown on Local Agricultural Wastes in Turkey. Int J Med Mushrooms. 2022;24(5):55-66
• Sharma VP, Kumar S, Tewari RP. Biological activities of Pleurotus spp. polysaccharides: A review. J Food Biochem. 2021;45(6):e13748
• Jayakumar T, Thomas PA, Geraldine P. In-vitro antioxidant activities of an ethanolic extract of the oyster mushroom, Pleurotus ostreatus. Innov Food Sci Emerg Technol. 2009;10(2):228-234
• Kalaras MD, Richie JP, Calcagnotto A, Beelman RB. Mushrooms: A rich source of the antioxidants ergothioneine and glutathione. Food Chem. 2017;233:429-433
• Li H, Zhang Z, Li M, Li X, Sun Z. Examining the Cultivation, Degradation Characteristics and Health Effects of the Golden Oyster Mushroom Pleurotus citrinopileatus (Agaricomycetes): A Review. Int J Med Mushrooms. 2023;25(4):1-14
• Correia de Barros TC, Garcia-Maniero S, Fonseca GG. Effect of different substrates on Pleurotus spp. cultivation in Brazil — Ergothioneine and lovastatin. J Food Compos Anal. 2022;105:104252
• Liu Y, Li S, Zhang Y, Sun Z. Research Progress on the Isolation, Purification, Structural Characteristics and Biological Activity Mechanism of Pleurotus citrinopileatus Polysaccharides. Molecules. 2025;30(13):2816
• Gregori A, Svagelj M, Pohleven J. Cultivation techniques and medicinal properties of Pleurotus spp. Food Technol Biotechnol. 2007;45(3):238-249

Connections

• Pleurotus genus relatives: Golden oyster mushroom is closely related to the common Oyster Mushroom (Pleurotus ostreatus), sharing the same genus and many overlapping bioactive compounds including beta-glucans, lovastatin, and ergothioneine. However, P. citrinopileatus is distinguished by its significantly higher ergothioneine content, making it a superior dietary source of this unique antioxidant amino acid.
• Beta-glucan immunomodulators: The polysaccharide-mediated immune activation of golden oyster mushroom operates through mechanisms shared with Maitake (Grifola frondosa), Shiitake (Lentinula edodes), and Turkey Tail (Trametes versicolor). The distinctive involvement of the Nrf2 pathway in P. citrinopileatus immunomodulation may differentiate its activity profile from other medicinal mushroom polysaccharides.
• Metabolic support fungi: The hypoglycemic and anti-obesity effects observed in preclinical models parallel research on Maitake (SX-fraction for insulin sensitivity) and Coprinus comatus (blood glucose regulation). The combination study with Lion’s Mane (Hericium erinaceus) suggests potential synergistic effects for metabolic support.
• Ergothioneine producers: Among cultivated medicinal mushrooms, P. citrinopileatus stands out as the richest source of ergothioneine, a compound increasingly recognized for cytoprotective and longevity-promoting properties. This unique attribute provides a rationale for dietary inclusion independent of the immunomodulatory polysaccharide research.
• Synergy potential: The combination of P. citrinopileatus with Oyster Mushroom would provide complementary Pleurotus-derived bioactives, while pairing with Maitake could offer synergistic metabolic support through different polysaccharide fractions and mechanisms of action.